ADVFN Logo ADVFN
Donnée du Marché
Actualité
Outils
Donnée du Marché
Discover

Hot Features

Follow Feed

Rester connecter avec les traders et investisseurs dans notre communauté Follow Feed.

Flux des Options

Explorez des données complètes sur les options et utilisez les filtres avancés avec Options Flow.

Moniteur

Organisez et surveillez vos d'actions et actifs avec le Moniteur.
Se connecter Premium IconPremium Help Menu
CAC 40
8 167,50
-0,26%
Dow Jones
40 003,59
0,34%
DAX
18 704,42
-0,11%
Brent Oil
83,76
0,00%
Bitcoin
66 927,41
-0,23%
Registration Strip Icon for monitor Surveillez plusieurs cotations en temps réel des principales bourses, telles que Euronext Paris, NASDAQ, NYSE, AMEX, Bovespa et plus encore.
S'inscrire
  1. Accueil
  2. Investir
  3. Actions
  4. Etats-Unis
  5. NASDAQ
  6. Achilles Therapeutics PLC (ACHL)

  7. Achilles Therapeutics PLC (ACHL) Actualités

ACHL

Achilles Therapeutics (ACHL)

Achilles Therapeutics PLC
De:
Trier par:
 Showing the most relevant articles for your search:NASDAQ:ACHL
DateHeureSourceTitreSymboleSociété
17/05/202423h15Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:ACHLAchilles Therapeutics PLC
17/05/202423h00GlobeNewswire Inc.Achilles Therapeutics Receives Nasdaq Deficiency Notice Regarding Minimum Bid Price RequirementNASDAQ:ACHLAchilles Therapeutics PLC
08/05/202413h00GlobeNewswire Inc.Achilles Therapeutics Reports First Quarter 2024 Financial Results and Recent Business HighlightsNASDAQ:ACHLAchilles Therapeutics PLC
04/04/202412h45GlobeNewswire Inc.Achilles Therapeutics Reports Fourth Quarter and Year-End 2023 Financial Results and Recent Business HighlightsNASDAQ:ACHLAchilles Therapeutics PLC
04/04/202412h30GlobeNewswire Inc.Achilles Therapeutics Provides Interim Phase I/IIa Update on Clonal Neoantigen Reactive T Cells in Advanced NSCLC and Melanoma Including First Patients Dosed with Enhanced Host ConditioningNASDAQ:ACHLAchilles Therapeutics PLC
05/02/202413h00GlobeNewswire Inc.Achilles Therapeutics to Present at the 10th Annual Immuno-Oncology 360 ConferenceNASDAQ:ACHLAchilles Therapeutics PLC
01/02/202419h14Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:ACHLAchilles Therapeutics PLC
18/12/202313h00GlobeNewswire Inc.Achilles Therapeutics Announces Publication of Nature Cancer ‘Comment’ on Strategy for Improved Neoantigen Immunogenicity PredictionNASDAQ:ACHLAchilles Therapeutics PLC
13/11/202322h30GlobeNewswire Inc.Achilles Therapeutics Reports Third Quarter 2023 Financial Results and Recent HighlightsNASDAQ:ACHLAchilles Therapeutics PLC
20/09/202314h45InvestorsHub NewsWirePathways to Progress: How Orphan Drug Designation Sparks Biotech TransformationNASDAQ:ACHLAchilles Therapeutics PLC
04/08/202313h00GlobeNewswire Inc.Achilles Therapeutics Reports Second Quarter 2023 Financial Results and Recent Business HighlightsNASDAQ:ACHLAchilles Therapeutics PLC
29/06/202322h04Edgar (US Regulatory)Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16 (6-k)NASDAQ:ACHLAchilles Therapeutics PLC
12/06/202314h00GlobeNewswire Inc.Achilles Therapeutics to Present at Upcoming ConferencesNASDAQ:ACHLAchilles Therapeutics PLC
10/05/202313h15GlobeNewswire Inc.Achilles Therapeutics Reports First Quarter 2023 Financial Results and Recent Business HighlightsNASDAQ:ACHLAchilles Therapeutics PLC
10/05/202313h00GlobeNewswire Inc.Achilles Therapeutics’ New Immunogenicity Prediction Application of its AI-Powered PELEUS™ Platform Uniquely Identifies the Most Potent T Cell AntigensNASDAQ:ACHLAchilles Therapeutics PLC
25/04/202313h00GlobeNewswire Inc.Achilles Therapeutics Announces Grant of US Patent Covering the Treatment of Patients with an Immunotherapy Targeting Neoantigens Based on Tumor HLA StatusNASDAQ:ACHLAchilles Therapeutics PLC
17/04/202314h00GlobeNewswire Inc.Achilles Therapeutics to Present at Chardan’s 7th Annual Genetic Medicines and Cell Therapy Manufacturing SummitNASDAQ:ACHLAchilles Therapeutics PLC
14/02/202322h03Edgar (US Regulatory)Amended Statement of Ownership (sc 13g/a)NASDAQ:ACHLAchilles Therapeutics PLC
30/12/202222h58Edgar (US Regulatory)Amended Statement of Beneficial Ownership (sc 13d/a)NASDAQ:ACHLAchilles Therapeutics PLC
09/11/202213h38TipRanksChardan Capital Keeps Their Buy Rating on Achilles Therapeutics (ACHL)NASDAQ:ACHLAchilles Therapeutics PLC
08/11/202215h29Edgar (US Regulatory)Securities Registration (foreign Private Issuer) (f-3)NASDAQ:ACHLAchilles Therapeutics PLC
25/07/202223h21Edgar (US Regulatory)Statement of Ownership (sc 13g)NASDAQ:ACHLAchilles Therapeutics PLC
02/05/202214h15TipRanksChardan Capital Thinks Achilles Therapeutics’ Stock is Going to RecoverNASDAQ:ACHLAchilles Therapeutics PLC
12/04/202213h30PR Newswire (US)The Center for Breakthrough Medicines (CBM) Strikes Multi-Year Deal with UK Cell Therapy PowerhouseNASDAQ:ACHLAchilles Therapeutics PLC
01/03/202215h00GlobeNewswire Inc.Achilles Therapeutics Selects Netrality’s 401 North Broad for United States HeadquartersNASDAQ:ACHLAchilles Therapeutics PLC
21/12/202114h00GlobeNewswire Inc.Achilles Therapeutics to present at the 40th Annual J.P. Morgan Healthcare ConferenceNASDAQ:ACHLAchilles Therapeutics PLC
20/12/202114h00GlobeNewswire Inc.Achilles Therapeutics Added to the NASDAQ Biotechnology IndexNASDAQ:ACHLAchilles Therapeutics PLC
09/12/202113h00GlobeNewswire Inc.Achilles Therapeutics Presents Positive Data at ESMO I-O Congress 2021 on High-Dose Manufacturing Process for Precision T Cell Therapies Targeting Clonal NeoantigensNASDAQ:ACHLAchilles Therapeutics PLC
12/11/202113h00GlobeNewswire Inc.Achilles Therapeutics Presents Data at the Society for Immunotherapy of Cancer (SITC) Annual Meeting Demonstrating the Ability to Detect, Quantify and Track Patient-specific cNeT and Significant Increase in cNeT Dose from VELOS™ Process 2 ManufacturingNASDAQ:ACHLAchilles Therapeutics PLC
09/11/202114h00GlobeNewswire Inc.Achilles Therapeutics Reports Third Quarter 2021 Financial Results and Recent Business HighlightsNASDAQ:ACHLAchilles Therapeutics PLC
 Showing the most relevant articles for your search:NASDAQ:ACHL

Dernières Valeurs Consultées

BIT
WINC26
Innovatec
COIN
METAGETH
METAG
BIT
F18003
Vontobel Financial Produ...
ASX
ESY
BIT
WMIB
Wisdomtree Ftse Mib
USOTC
SPHDD
Santhera Pharmaceuticals (CE)
LSE
CCPD
NYSE
LPL
LG Display
TSX
MBX
Microbix Biosystems
TSXV
REW.H
Rewardstream Solutions
NYSE
KIM-K.CL
Kimco Realty
NASDAQ
GNOGW
Golden Nugget Online Gam...
USOTC
PUBGY
Publicis Groupe (QX)
EU
FLU36
Fluxys Finance
TSX
HTA.U
Harvest Tech Achievers G...
TSXV
PEZM.H
PEZM Gold
Delayed Upgrade Clock
ADVFN Logo

France
Société
Entreprise
Popular
Obtenir l'application

Assistance: support@advfn.fr

En accédant aux services disponibles de ADVFN, vous acceptez les Conditions Générales de ADVFN Conditions Générales

© 2024 ADVFN PLC - Tous droits réservés